We can provide GMP validation service that complies with SFDA, FDA, WHO and EU EMPA.Excellent registration team could help us easlily to register our products in different countries.If you and your customer are interested in some products or need CMO business service because of capacity limit, product cost limit or developing limit, plz feel free to contact us. 

Besides, we could discuss the possible FDF distribution business. Hope to get the chance to discuss deeply.

Hangzhou Jinlan Pharm-Drugs Technology Co., Limited  is located in Hangzhou, Zhejiang Province. Neighboring Ningbo port, Shanghai port, Hangzhou Xiaoshan Int’l Airport and Shanghai Pudong Int’l Airport, the transportation and production environment are excellent.

We have established well market channels both domestically and overseas. Now JINLAN PHARMA is authorized by some Chinese chemical factories as universal agency and international area agency. Our products are exported to more than 100 countries and enjoy a well reputation, including Europe, USA, South America, India, south-east Asia and so on. Such as Canada, Germany, Spain, Australia, Russia, UAE, Estonia, Indonesia, Egypt, Pakistan and so on. Our machines with Excellent quality, Competitive price, Good after-service, are highly welcomed by our customers. We are pleased to know you and hope to be good friend and cooperator with you for our products. I am sure you will be satisfied with us.

Based on the philosophy of “Human-orient, Technical first, Quality product and High efficiency, Fact and Innovation”, JINLAN PHARMA highly welcome friends from all over the world to cooperate and get co-development. 

Description

Avibactam is a non-β-lactam β-lactamase inhibitor developed by Actavis (now Allergan) jointly with AstraZeneca. A new drug application for avibactam in combination with ceftazidime (branded as Avycaz) was approved by the FDA on February 25, 2015, for treating complicated urinary tract (cUTI) and complicated intra-abdominal infections (cIAI) caused by antibiotic resistant-pathogens, including those caused by multi-drug resistant Gram-negative bacterial pathogens.
Increasing resistance to cephalosporins among Gram-(−) bacterial pathogens, especially among hospital-acquired infections, results in part from the production of β-lactamase enzymes that deactivate these antibiotics. While the co-administration of a β-lactamase inhibitor can restore antibacterial activity to the cephalosporin, previously approved β-lactamase inhibitors such as tazobactam and clavulanic acid do not inhibit important classes of β-lactamases, including Klebsiella pneumoniae carbapenemases (KPCs), New Delhi metallo-β-lactamase 1 (NDM-1), and AmpC-type β-lactamases. Whilst avibactam inhibits class A, class B, and, some, class D serine β-lactamases (such as KPCs, AmpC), it has been reported to be a poor substrate/weak inhibitor of class B metallo-β-lactamases, such as VIM-2, VIM-4, SPM-1, BcII, NDM-1, Fez-1.

Basic Info